Zotepine

Zotepine is an atypical antipsychotic drug that is used in the treatment of schizophrenia. It was developed by Fujisawa Pharmaceutical and was first introduced in Japan in 1982. Zotepine is not approved for use in the United States, United Kingdom, or Canada, but is available in various other countries worldwide.

Pharmacology

Zotepine, like other atypical antipsychotics, is considered a multireceptor antagonist, but it also has reuptake inhibitor properties. It has high affinity for the dopamine D1, D2, and D3 receptors, the serotonin 5-HT2A and 5-HT2C receptors, the histamine H1 receptors, and the alpha-1 adrenergic receptors, and moderate affinity for the muscarinic acetylcholine receptors.

Side effects

The most common side effects of zotepine are somnolence, dry mouth, weight gain, akathisia, tachycardia, and orthostatic hypotension. Less common side effects include leukopenia, neutropenia, agranulocytosis, seizures, QT interval prolongation, hyperprolactinemia, and neuroleptic malignant syndrome.

See also

• List of antipsychotics
• Atypical antipsychotic

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  Zotepine
• 
  Zotepine ball-and-stick model
• 
  Zotepine synthesis pathway